MEKK2 mediates aberrant ERK activation in neurofibromatosis type I
Open Access
- 11 November 2020
- journal article
- research article
- Published by Springer Science and Business Media LLC in Nature Communications
- Vol. 11 (1), 1-10
- https://doi.org/10.1038/s41467-020-19555-6
Abstract
Neurofibromatosis type I (NF1) is characterized by prominent skeletal manifestations caused by NF1 loss. While inhibitors of the ERK activating kinases MEK1/2 are promising as a means to treat NF1, the broad blockade of the ERK pathway produced by this strategy is potentially associated with therapy limiting toxicities. Here, we have sought targets offering a more narrow inhibition of ERK activation downstream of NF1 loss in the skeleton, finding that MEKK2 is a novel component of a noncanonical ERK pathway in osteoblasts that mediates aberrant ERK activation after NF1 loss. Accordingly, despite mice with conditional deletion of Nf1 in mature osteoblasts (Nf1(fl/fl);Dmp1-Cre) and Mekk2(-/-) each displaying skeletal defects, Nf1(fl/fl);Mekk2(-/-);Dmp1-Cre mice show an amelioration of NF1-associated phenotypes. We also provide proof-of-principle that FDA-approved inhibitors with activity against MEKK2 can ameliorate NF1 skeletal pathology. Thus, MEKK2 functions as a MAP3K in the ERK pathway in osteoblasts, offering a potential new therapeutic strategy for the treatment of NF1. Neurofibromatosis type I (NF1) is characterized by prominent skeletal abnormalities mediated in part by aberrant ERK pathway activation due to NF1 loss-of-function. Here, the authors report the MEKK2 is a key mediator of this aberrant ERK activation and that MEKK2 inhibitors, including ponatinib, ameliorate skeletal defects in a mouse model of NF1.Funding Information
- National Research Foundation of Korea (2017R1A6A3A03003075)
- U.S. Department of Health & Human Services | National Institutes of Health (R01AR075585)
- U.S. Department of Defense (NF150055)
- Burroughs Wellcome Fund (DP5OD021351)
This publication has 44 references indexed in Scilit:
- Sustained MEK inhibition abrogates myeloproliferative disease in Nf1 mutant miceJCI Insight, 2012
- MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumorsJCI Insight, 2012
- Mice lacking Nf1 in osteochondroprogenitor cells display skeletal dysplasia similar to patients with neurofibromatosis type IHuman Molecular Genetics, 2011
- Potent Activity of Ponatinib (AP24534) in Models of FLT3-Driven Acute Myeloid Leukemia and Other Hematologic MalignanciesMolecular Cancer Therapeutics, 2011
- The p38 MAPK pathway is essential for skeletogenesis and bone homeostasis in miceJCI Insight, 2010
- Extracellular Signal-Regulated Kinase 1 (ERK1) and ERK2 Play Essential Roles in Osteoblast Differentiation and in Supporting OsteoclastogenesisMolecular and Cellular Biology, 2009
- AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based ResistanceCancer Cell, 2009
- A-Raf and B-Raf Are Dispensable for Normal Endochondral Bone Development, and Parathyroid Hormone-Related Peptide Suppresses Extracellular Signal-Regulated Kinase Activation in Hypertrophic ChondrocytesMolecular and Cellular Biology, 2008
- Cardiotoxicity associated with tyrosine kinase inhibitor sunitinibThe Lancet, 2007
- Critical role of the extracellular signal–regulated kinase–MAPK pathway in osteoblast differentiation and skeletal developmentThe Journal of cell biology, 2007